Recent Updates on Wnt Signaling Modulators: A Patent Review (2014-2020)

The document is a comprehensive review of patents related to Wnt signaling modulators from 2014 to 2020, with a focus on their therapeutic potential for various diseases, including cancer and androgenetic alopecia. It details 104 PCT applications by 32 different organizations, with a particular emphasis on the development of small molecules and antibodies targeting the Wnt pathway. Two drugs, lorecivivint for knee osteoarthritis and SM-04554 for androgenetic alopecia, are highlighted as being in Phase III clinical trials. Additionally, 13 molecules are in various stages of clinical trials, with Samumed LLC being a significant contributor with over 37 PCTs. The review also discusses the chemical scaffolds explored for Wnt modulation and the promising in vitro and in vivo results of several compounds, such as compound 48 with an IC50 of 0.0917 µM and compound 99 with significant antitumor activity. The document underscores the importance of the Wnt pathway in disease treatment and the anticipation of clinical trial results to further understand the roles of these modulators.